NL-OMON36117已完成不适用
A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjects - [14C]-TAK-700 tracer label human ADME study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy male subject
- •18-55 years, incl
- •BMI 18-30 kg/m2, incl
排除标准
- •Suffering from : hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of the study. In case of donating any blood or significant loss of blood within 60 days of the start of drug dosing.
研究者
相似试验
已完成
不适用
A phase 1 study to investigate the absorption, metabolism and excretion of [14C] AT1001 (migalastat hydrochloride) following a single oral administration in healthy volunteers.NL-OMON35820Amicus Therapeutics, Inc.6
已完成
不适用
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of 14C-PTC299 Following Multiple Oral Dose Administrations in Healthy VolunteersAcute LeukemiaNL-OMON50826PTC Therapeutics, Inc.7
已完成
不适用
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of PTC857 Following Oral Administration of a Single Dose of 14C-PTC857 at Steady-State Conditions in Healthy Male Volunteers.NL-OMON51552PTC Therapeutics, Inc.8
已完成
不适用
A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of Radiolabeled [14C] R924548 Following Single Oral Dose Administration in Healthy Male Subjectsimmune-mediated diseasesrheuma10003816NL-OMON37118Rigel Pharmaceuticals, Inc6
已完成
1 期
Mass Balance Study of [14C]-S-600918 Oral Suspension in Healthy Male SubjectsHealthy subjectsJPRN-jRCT1080225285Shionogi B.V.6